Payment overview · 2025
General Payments
$591.89
24 reported records · 13 companies
Healthcare provider profile · identity verified
Fred W Rohm, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT WORTH, TX · NPI 1407894926
Verified facts
What the public records show
CMS Open Payments records show Fred W Rohm, DO received $591.89 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.07 | 23.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.83 | 14.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $84.44 | 14.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.71 | 9.2% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $49.12 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.51 | 7.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.08 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.88 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.15 | 3.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.06 | 3.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.16 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.17 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.71 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $591.89 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $141.07 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.83 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $84.44 | 4 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $49.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 318 | 40 |
| Losartan Potassium | Losartan Potassium | 260 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 30 |
| Lisinopril | Lisinopril | 178 | 46 |
| Gabapentin | Gabapentin | 152 | 41 |
| Nifedipine Er | Nifedipine | 126 | 36 |
| Omeprazole | Omeprazole | 123 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 113 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 111 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 27 |
| Metformin Hcl | Metformin Hcl | 109 | 35 |
| Tramadol Hcl | Tramadol Hcl | 102 | 20 |
| Prednisone | Prednisone | 98 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 29 |
| Azithromycin | Azithromycin | 93 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 16 |
| Methylprednisolone | Methylprednisolone | 91 | 72 |
| Clonazepam | Clonazepam | 86 | 13 |
| Simvastatin | Simvastatin | 84 | 23 |
| Carvedilol | Carvedilol | 83 | 25 |
| Alendronate Sodium | Alendronate Sodium | 78 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Meloxicam | Meloxicam | 71 | 21 |
| Furosemide | Furosemide | 66 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 20 |
| Trazodone Hcl | Trazodone Hcl | 63 | 16 |
| Ezetimibe | Ezetimibe | 59 | 15 |
| Potassium Chloride | Potassium Chloride | 57 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 45 |
| Estradiol | Estradiol | 52 | 15 |
| Ozempic | Semaglutide | 52 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 17 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 15 |
| Myrbetriq | Mirabegron | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Eliquis | Apixaban | 41 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 17 |
| Temazepam | Temazepam | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 17 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | 11 |
| Famotidine | Famotidine | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 13 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 14 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $591.89 · 24 records | Amgen Inc. | AREXVY, CAPLYTA, Cologuard Collection Kit, EVENITY, Fluad, Flucelvax, GEMTESA, INSPIRE, KEVEYIS, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error